GlassScriptPhysician profile
Kimberly Gonzalez
NPI 1902364151
$2,649.41
in general payments reported to CMS, 2019-2025
34 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $868 · 2023: $792 · 2024: $459 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.50 | 2022-2025 | Sogroya, Rybelsus, Ozempic |
| Corcept Therapeutics | $220.80 | 2022-2023 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.14 | 2022 | |
| Dexcom, INC. | $177.25 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $124.79 | 2022 | |
| Amgen INC. | $124.70 | 2023 | Evenity |
| Biohaven Pharmaceuticals, INC. | $122.91 | 2021 | |
| Pfizer INC. | $106.81 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $106.09 | 2025 | |
| Glaxosmithkline, LLC. | $101.64 | 2025 | Penmenvy |
| Lilly USA, LLC | $90.94 | 2021-2023 | Mounjaro, Trulicity |
| Acadia Pharmaceuticals INC | $79.55 | 2024 | Daybue |
| Horizon Therapeutics Plc | $70.79 | 2022 | |
| Cranial Technologies, INC | $65.62 | 2024 | Doc Band |
| Verrica Pharmaceuticals INC. | $63.20 | 2024 | Ycanth |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $54.73 | 2024 | Grastek, Ragwitek, Odactra |
| Merck Sharp & Dohme LLC | $44.54 | 2022-2024 | Proquad, Vaxneuvance, Gardasil 9 |
| Abbott Laboratories | $44.11 | 2023 | Freestyle Libre 3 |
| Medtronic, INC. | $42.85 | 2022 | |
| Amryt Pharma Holdings LTD | $39.53 | 2022-2023 | Mycapssa |
| Irhythm Technologies, INC. | $38.46 | 2024 | Zio Xt Patch, Zio Monitor |
| Ultragenyx Pharmaceutical INC. | $37.60 | 2023-2024 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $31.64 | 2024-2025 | Zoryve |
| Ascendis Pharma Endocrinology INC | $30.98 | 2023 | |
| Novartis Pharmaceuticals Corporation | $29.25 | 2022 | |
| Ascensia Diabetes Care US INC. | $26.48 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.01 | 2022 | |
| Sanofi Pasteur INC. | $23.73 | 2023 | |
| Halozyme INC | $23.66 | 2023 | |
| Radius Health, INC. | $21.19 | 2022 | |
| Lnhc, INC | $16.70 | 2025 | Zelsuvmi |
| Abbvie INC. | $16.15 | 2024 | |
| Kyowa Kirin, INC. | $15.83 | 2023 | |
| Ibsa Pharma INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.